|
|
News Breaks | | | | February 4, 2013 | | 07:16 EDT |  | JAZZ | Jazz consensus expectations too low, says Lazard Capital
Lazard Capital believes consensus expectations for Jazz Pharmaceuticals are too low following the company's Xyrem price increase last week. The firm keeps a Buy rating on the stock with an $87 price target. | |
|
News For JAZZ From The Last 14 Days Check below for free stories on JAZZ the last two weeks. |
|
|
| May 20, 2013 | | 11:18 EDT |  | JAZZ | High option volume stocks: JASO QUIK FWLT NM JAZZ
 Subscribe for More Information | |
|
|
|
|
|
|
